Literature DB >> 11724304

HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions.

A Facoetti1, E Capelli, R Nano.   

Abstract

It is generally accepted that human and experimental tumour cells can lose Major Histocompatibility Complex (MHC) class I molecules and this represents the major mechanism of tumour escape from T-cell immune responses. Nevertheless testing of HL4 class I antigen expression in malignant lesions is not routinely used to evaluate the immunological conditions of the patients because of the pathologists' reluctance to utilise frozen tissue sections in immunocytochemisty. We analysed the expressions of HLA class I molecule and beta2-microglobulin in normal and neoplastic tissues, comparing different samples and methods. The expression of HLA receptors was studied in 7 brain tumours, 10 colon adenocarcinoma and 2 breast carcinoma by immunocytochemical technique. 4 normal tissues and peripheral blood mononucleated cells were analysed as positive control. The peroxidase staining method was performed on fresh imprints, frozen sections, formalin- fixed tissues and fine-needle aspirates. The results indicated that the best and simplest conditions for the detection of HLA molecules were obtained using fresh imprints and fine-needle aspirates.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11724304

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  HLA-DRB1 allele polymorphisms in genetic susceptibility to esophageal carcinoma.

Authors:  Jun Lin; Chang-Sheng Deng; Jie Sun; Xian-Gong Zheng; Xing Huang; Yan Zhou; Ping Xiong; Ya-Ping Wang
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.